Bibliography
- Beatson GT. On the treatment of inoperable cases of carcinogen of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7, 162-7
- Dellapasqua S, Castiglione-Gertsch M. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not. Breast 2005;14(6):555-63
- Maucort-Boulch D, Roy P. Modeling the effect of tamoxifen chemoprevention on long-term mortality in white women at high risk of breast cancer. Eur J Cancer Prev 2006;15(4):347-52
- Patani N, Cutuli B, Mokbel K. Current management of DCIS: a review. Breast Cancer Res Treat 2007 [Epub ahead of print]
- Wu M, Goss PE. Update on the use of letrozole in breast cancer. Expert Opin Pharmacother 2007;8(14):2329-45
- Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, ‘pure’ antiestrogen. Cancer 2000;89:817-25
- Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003;8:335-41
- Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87(3):905-31
- Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-31
- Pietras RJ, Szego CM. Plasma membrane for steroid hormones in cell signalling and nuclear function. In: Endocrinology: Basic and Clinical Principles, Melmed S, Conn PM, editors. Second Edition. Totowa, NJ: Humana Press; 2005. p. 67-84
- Freeman MR, Cinar B, Lu ML. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005;16:273-9
- Masamura S, Santner SJ, Heitjan DF, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25
- Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin Cancer Res 2004;10:337S-345S
- Santen R, Jeng MH, Wang JP, et al. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001;79:115-25
- Yue W, Santen RJ, Wang J-P, et al. Aromatase within the breast. Endocr Relat Cancer 1999;6:157-64
- Berstein LM, Zheng H, Yue W, et al. New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 2003;10:267-77
- Shim WS, Conaway M, Masamura S, et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396-405
- Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4
- Kinoshita Y, Chen S. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor α. Cancer Res 2003;63:3546-55
- Marquez DC, Lee J, Lin T, et al. Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 2001;16:73-81
- Britton DJ, Hutcheson IR, Knowlden JM, et al. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006;96(2):131-46
- Sommer A, Hoffmann J, Lichtner RB, et al. Studies on the development of resistance to the pure antiestrogen Faslodex™ in three human breast cancer cell lines. Steroid Biochem Mol Biol 2003;85:33-47
- Lipton A, Ali SM, Leitzel K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-72
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-1/neu oncogene. Science 1987; 235:177-82
- Pietras RJ, Marquez DC, Chen H-W, et al. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signaling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat 2003;82(Suppl 1):12-3
- Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004;10(11):3621-8
- Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003;63:6523-31
- Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003;9(1 Pt 2):511S-515S
- Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 2003;9:361-73
- Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616-22
- Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005;19:1951-9
- Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 2006;13(3):905-19
- Hyder SM, Nawaz Z, Chiappetta C, et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000;60:3183-90
- Ruohola JK, Valve EM, Karkkainen MJ, et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999;149:29-40
- Rydén L, Jirström K, Bendahl P-O, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005;23:4695-704
- Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11(2 Pt 2):865S-870S
- Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61
- Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20:5041-7
- Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-50
- Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu crosstalk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35
- Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin Oncol 2001;19:3808-16
- Dowsett M. Analysis of time to recurrence in the ATAC (Arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82:S7
- Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
- Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95
- Albain K, Elledge R, Gradishar WJ, et al. Open-label Phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76:A20
- Baselga J, Albanelli J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003;22:A24
- Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib (ZD1839) is active in acquired tamoxifen resistant oestrogen receptor positive and ER-negative breast cancer: results from a Phase II study. Proc Am Soc Clin Oncol 2003;22:A23
- Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with breast cancer: a double-blind placebo-controlled Phase II randomised trial. Lancet Oncol 2005;6:383-91
- Vogel C, Cobleigh MA, Tripathy D, et al. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001;37(Suppl 1):S25-9
- Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102(1):43-9
- MacKey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006;100(Suppl 1):S5, SABCS 2006, (Abstract 3)
- Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/erbB2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94
- Spector N, Raefsky E, Hurwitz H, et al. Safety, clinical efficacy, and biological assessments from EGF10004; a randomised Phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc Am Soc Clin Oncol 2003;22:A772
- Blackwell KL, Kaplan EH, Franco SX, et al. A Phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2004;22:3006
- Chu Q, Goldstein L, Murray N, et al. A Phase I, open label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. Proc Am Soc Clin Oncol 2005;23:192S (A3001)
- Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492-9
- Lebowitz PF, Eng-Wong J, Balis F, et al. A Phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormonereceptor positive metastatic breast cancer. Proc Am Soc Clin Oncol 2004;22:644
- Li T, Christos P, Sparano JA, et al. Phase II study of the farnesyl transferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor-positive breast cancer: New York Cancer Consortium Trial P6205. ASCO Ann Meet Proc 2007;1037
- DeGraffenried LA, Friedrichs WE, Russel DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004;10:8059-67
- Rudolf J, Boulay A, Zumstein-Mecker S, et al. The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative FAD001 with the aromatase inhibitortletrozole in breast carcinomas. Proc Am Assoc Cancer Res 2004;45:A5619
- Baselga J, Fumoleau P, Gil M, et al. Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. Proc Am Soc Clin Oncol 2004;23:13 (A544)
- Carpenter JT, Roche H, Campone M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2005;23:21S (A564)
- Miller KD, Sledge GW, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: a review of studies presented at the 2006 san antonio breast cancer symposium. Clin Adv Hematol Oncol 2007;5(3):1-12
- Cobleigh MA, Langmuir VK, Sledge GW, et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24
- Traina TA, Rugo H, Caravelli J, et al. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 2006;24,18S(June 20 Suppl):3050
- Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007;12(7):756-65
- Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102(1):43-9
- Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled Phase II randomised trial. Lancet Oncol 2005;6(6):383-91